OBJECTIVE:
The overall goal of the Pepper Study Registry (PSR) is to guarantee the proper collection, transfer, and central storage of biological tissue (e.g., blood, skeletal muscle, adipose tissue, cartilage and DNA) to be used for conducting future ancillary studies by investigators with an interest in aging-related research.SPECIMEN INVENTORY:
As of August 2020 the Registry holds >184,273 total stored cryosamples (blood >169,342, urine >7,562, DNA >5,290, and tissue> 2,115) collected from >8,000 research participants enrolled in 65 different studies (ongoing and completed). The table provided lists the available samples and a brief description of the participants from each of the studies.All samples are collected from study participants enrolled in research protocols at Wake Forest University, Wake Forest University Health Sciences, or other collaborating institutions. Written informed consent is obtained from each participant providing permission to have their samples stored for future, undesignated research. All samples are stored in labeled cryovials in -80oC freezers located in a locked room on the M floor of the Nutrition Research Building at WFUHS. The freezers are connected to an emergency power supply and a CO2 back-up system.
REQUISITION OF SAMPLES:
- Only investigators (both within and outside WFUHS) with IRB-approved ancillary study proposals will be provided samples from the Registry for analyses
- All samples are identified by a unique ID which is linked to personal identifiers and other study-related data that are maintained only by the individual study’s Principal Investigator. Thus, investigators who wish to utilize samples for ancillary research will need to involve and collaborate with the PI and investigators of the original study
- Samples will be released to investigators de-identified (as defined by the HIPAA Privacy Rule) to protect the privacy and confidentiality of study subjects
Contact the Registry Coordinator at (336) 713-7126 or PepperCenter@WakeHealth.edu for additional information.
How to search: Enter any single word, or combination of words using " + " (space plus space) in between. As an example, to search for both male and female with a condttion of obesity that have DEXA, enter "DEXA + Obesity + M/F". Clicking a column header will sort the data by that column's data.
Notes: Most studies will have some available demographic and many will have laboratory data. An asterisks (*) indicate study collected by not available in the database.
Notes: Most studies will have some available demographic and many will have laboratory data. An asterisks (*) indicate study collected by not available in the database.
Study (PI) | Gender | Age | Disease/ Condition |
N= | Design / Intervention |
Biospecimen | Imaging | Physical | Activity Monitoring |
Cognitive / Depression |
---|---|---|---|---|---|---|---|---|---|---|
Functional near-infr...
(Huppert, Pittsburgh) |
M/F | 19 | cross-sectional cohort |
|
DSST Stroop |
|||||
This study measured ...
(Hergenroeder, Pittsburgh) |
M/F | 69 -98 | 43 | cross-sectional cohort |
|
ActivPAL |
||||
7 activity monitors ...
(Hergenroeder, Pittsburgh) |
M/F | 69 -98 | 43 | cross-sectional cohort |
|
Actigraph (Wrist) Actigraph (Hip) ActivPAL Fitbit |
||||
ADAPT
(Messier, WFU) |
M/F | 60 + | knee osteoarthritis | 316 | exercise / diet 18 mos |
|
Gait Speed
PAT-D |
MMSE CES-D |
||
APPLE
(Nicklas, WFU) |
M/F | 65 -79 | Arthritis, OA, weight loss | 40 | weight loss: no vest vs weighted vest 22 weeks |
Serum Plasma Adipose |
DEXA
|
Gait Speed
ESPPB Leg Press Knee Extensor |
MoCA CES-D |
|
Bicarb
(Petrovic, WFU) |
M/F | 65 + | Kidney disease / disability | 80 | 3 months RCT oral bicarbonate supplement vs placebo |
Serum Plasma Urine |
DEXA
|
Gait Speed
SPPB |
MoCA |
|
CLIP
(Rejeski, WFU) |
M/F | 60 -79 | Overweight/obese; CVD or METs | 288 | 18-month RCT Caloric Restriction and/or Aerobic Exercise |
Serum Plasma |
DEXA
|
Gait Speed
SPPB PAT-D |
||
CLIP II
(Rejeski, WFU) |
M/F | 60 -79 | cardiovascular disease | 252 | Weight Loss alone, aerobic exercise training +Weight Loss or resistance exercise training +Weight Loss 18 mos |
DEXA*
|
SPPB* Knee Extensor* |
Actigraph (Hip)* |
||
COCOA-PAD II
(McDermott, NW) |
M/F | 55 + | Peripheral artery disease | 190 | RCT cocoa flavanols |
Serum Plasma DNA |
MRI
|
Gait Speed
SPPB CPET |
Actigraph (Hip) |
MMSE |
DEMO
(Nicklas, WFU) |
F | 50 -70 | Abdominal obesity | 112 | 5-month RCT Caloric Restriction vs. CR + Aerobic Exercise |
Serum Plasma Adipose DNA |
DEXA
|
Grip Strength SPPB PAT-D |
MMSE CES-D |
|
EFFECT - Pilot
(Morris, WFU) |
M/F | 18 + | ICU patients | 100 | Cross-sectional Intensive physical therapy vs. Usual Care |
Serum Plasma DNA |
|
|||
EMPOWER
(Nicklas, WFU) |
M/F | 65 -85 | Obesity | 189 | Randomized to 3 treatment arms 18 mos |
Serum Plasma |
DEXA
|
Gait Speed
Grip Strength ESPPB |
ActivPAL* |
DSST MoCA CES-D |
EVIDENCE
(Houston, WFU) |
M/F | 65 + | Vitamin D Insufficient | 200 | Vitamin D vs Placebo 12 month |
Serum Muscle |
|
Gait Speed
Grip Strength SPPB ESPPB Leg Press Knee Extensor CHAMPS Postural Sway Gait Rite |
DSST MoCA Story Recall* CES-D |
|
EVIDENCE Sub Study
(Molina, WFU) |
M/F | 65 + | Vitamin D Insufficient | 40 | Vitamin D & Muscle Function 4 months |
Serum Plasma |
|
Gait Speed
Grip Strength SPPB ESPPB Leg Press |
MoCA |
|
FIT (F/U Infinite)
(Nicklas, WFU) |
M/F | 65 -80 | obesity, follow up to INFINITE Study | 0 | 18 mos |
Plasma DNA |
|
Gait Speed
ESPPB CHAMPS* |
DSST MMSE CES-D |
|
FLOW
(Hundley, WFU) |
M/F | 50 + | Aging/Heart Failure | 30 | Cross-sectional N/A |
Serum Plasma |
|
Grip Strength SPPB PAT-D |
||
GIFT II
(McDermott, NW) |
M/F | 55 + | Peripheral artery disease | 30 | RCT unacylated ghrelin |
Serum Plasma DNA |
MRI
|
Gait Speed
SPPB CPET |
MMSE |
|
GO MET
(Ding, WFU) |
M/F | 65 -79 | CAD / Cancer / MCI / Physcial Function Decline | 30 | Crossover Metformin vs Placebo 24 months |
Serum Plasma DNA |
|
Gait Speed
Grip Strength ESPPB PAT-D Leg Press Knee Extensor* |
DSST MoCA |
|
Healthy Aging
(Kitzman, WFU) |
M/F | 60 + | Healthy controls | 61 | Cross-sectional N/A |
Serum Plasma Urine Muscle DNA |
DEXA
|
Gait Speed
Grip Strength SPPB PAT-D Leg Press Knee Extensor CHAMPS |
ActivPAL* |
MMSE Rey AVLT* Trail Making* |
HI-PAD
(McDermott, NW) |
M/F | 55 + | Peripheral artery disease | 39 | RCT VM202 |
Serum Plasma DNA |
CT
MRI |
Gait Speed
SPPB CPET |
MMSE |
|
HOPE - Pilot
(Houston, WFU) |
M/F | 55 + | Obesity | 54 | Exercise Study Follow up / Feasibility Study n/a |
DEXA
|
Gait Speed
Grip Strength SPPB* ESPPB Leg Press Knee Extensor* |
DSST* MoCA Rey AVLT* TICS* Trail Making* CES-D* |
||
I'M FIT
(Nicklas, WFU) |
M/F | 65 -79 | Obese; at risk for disability | 130 | 5-month RCT Resistance Training (RT) vs. Resistance Training (RT) + Caloric Restriction |
Serum Plasma Muscle Adipose |
CT
DEXA |
Gait Speed
Grip Strength SPPB ESPPB PAT-D Leg Press Knee Extensor |
MMSE |
|
IDEA
(Messier, WFU) |
M/F | 55 + | Overweight/obese; Knee OA | 450 | 18-month RCT Caloric Restriction vs. Aerobic Exercise vs. CR+AEX |
Serum Plasma Urine DNA |
CT
DEXA |
Gait Speed
Grip Strength SPPB PAT-D Leg Press |
ActivPAL* |
DSST MMSE 3MSE CES-D |
INFINITE
(Nicklas, WFU) |
M/F | 65 -79 | Obese | 180 | 5-month RCT Aerobic Exercise vs AEX + Hi Caloric Restriction vs AEX + Low Caloric Restriction |
Serum Plasma Adipose DNA |
DEXA
|
Gait Speed
SPPB PAT-D |
RT3* |
DSST MMSE Rey AVLT* COWA* Stroop* CES-D |
INTERCEDE
(McDermott, NW) |
M/F | 55 + | Peripheral artery disease | 230 | RCT Intermittent Pneumatic Compression (IPC) with and without exercise |
Serum Plasma DNA |
MRI
|
Gait Speed
SPPB CPET |
Actigraph (Wrist) |
MMSE Stroop |
LIFE - Pilot
(Kritchevsky, WFU) |
M/F | 70 -89 | At risk for disability | 424 | 12-month RCT Aerobic + Resistive Exercise vs. Control |
Serum Plasma DNA |
DEXA*
|
Gait Speed
Knee Extensor* |
CES-D* |
|
LOSE-IT
(Miller, WFU) |
M/F | 18 + | Bariatric surgery patients | 42 | Cross-sectional N/A |
Serum Plasma Muscle Adipose |
CT
DEXA |
SPPB PAT-D Knee Extensor* |
CES-D |
|
MAT-PAC
(Kim, WFU) |
M/F | 65 + | Mobility | 0 | observational |
|
||||
Medifast
(Beavers, WFU) |
M/F | 65 -79 | Obesity | 124 | Weight Loss (High Protein Group) / Weight Stable group 24 mos |
Serum Plasma Urine |
DEXA*
|
Gait Speed
Grip Strength SPPB* ESPPB PAT-D Leg Press |
Actigraph (Wrist)* |
DSST MoCA CES-D |
MidCog
(Wolf, NW) |
M/F | 40 -64 | 1200 | observational longitudinal cohort study N/A |
|
Gait Speed
Grip Strength |
Actigraph (Wrist) |
MoCA Story Recall |
||
MORPH
(Brooks, WFU) |
M/F | 55 -85 | Obesity / Pain | 35 | (2) a two group randomized controlled pilot trial (RCT) in 35 obese (BMI=30-45 kg/m2), low-active, older (55-85 years) adults with chronic pain randomized to either 12-weeks of active intervention or a wait-list control. 12 weeks |
|
ESPPB |
MoCA CES-D |
||
MOW Vitamin D
(Houston, WFU) |
M/F | 65 + | Vitamin D Insufficient | 68 | 100,000 IU OF VITAMIN D VS PLACEBO (400 IU VIT E) AND FALLS ASSESSMENT 5 month Randomized Control Trial |
Serum Plasma |
|
PAT-D* |
||
NICE
(McDermott, NW) |
M/F | 18 + | Peripheral artery disease | 90 | RCT Nicotinamide riboside, resveratrol |
Serum Plasma DNA |
|
Gait Speed
SPPB CPET |
MMSE |
|
OPTIFAST
(Ard, WFU) |
M/F | 64 + | Obesity / Disability | 88 | high intensity weight loss protocol VS a moderate intensity weight loss protocol 26 weeks |
DEXA
|
Gait Speed
ESPPB Knee Extensor |
DSST MoCA |
||
OPTIMA
(Kritchevsky, WFU) |
M/F | 65 -79 | Overweight/obese; at risk for disability | 88 | 6-month RCT Caloric Restriction + Pioglitazone vs. CR + Resistance Exercise |
Serum Plasma Muscle |
CT
DEXA |
Gait Speed
Grip Strength SPPB ESPPB PAT-D Leg Press Knee Extensor* CHAMPS |
MMSE CES-D |
|
PACT
(Miller, WFU) |
M/F | 60 + | Overweight/obese; Knee OA | 84 | 6-month RCT Caloric Restriction + Exercise vs. Control |
Serum Plasma Muscle DNA |
DEXA
|
Gait Speed
PAT-D* |
||
PAIN
(Brooks, WFU) |
M/F | 65 + | chronic pain | 33 | observational 3 months |
|
SPPB PAT-D |
|||
PART - Transplant
(Hartmann, WFU) |
M/F | 60 + | Renal Transplant | 30 | physical activity 3 months |
Serum Urine |
DEXA
|
Gait Speed
Grip Strength SPPB PAT-D Leg Press CHAMPS |
Actigraph (Hip)* |
MMSE CES-D |
PERMET
(McDermott, NW) |
M/F | 18 + | Peripheral artery disease | 212 | RCT metformin |
Serum Plasma DNA |
|
Gait Speed
SPPB CPET |
MMSE |
|
PIE
(Kitzman, WFU) |
M/F | 60 + | Diastolic heart failure | 80 | 12-month RCT ACE inhibitor use vs Placebo |
Serum Plasma Muscle DNA |
DEXA
|
Grip Strength SPPB PAT-D |
||
PIE II
(Kitzman, WFU) |
M/F | 60 + | Diastolic heart failure | 80 | 12-month RCT Spironolactone vs Placebo |
Serum Plasma Muscle DNA |
DEXA
|
Grip Strength SPPB PAT-D |
||
POWER
(Marsh, WFU) |
M/F | 65 + | At risk for disability | 45 | 3-month RCT Strength training vs. Power training vs. Control |
Serum Plasma Muscle |
DEXA
|
SPPB PAT-D |
CES-D |
|
PREDICT
(Hundley, WFU) |
M/F | 55 -85 | At risk for CHF | 608 | Longitudinal cohort N/A |
Serum DNA |
MRI
|
Gait Speed
Grip Strength SPPB PAT-D Leg Press |
||
PROVE
(McDermott, NW) |
M/F | 18 -90 | Peripheral artery disease | 212 | RCT Weight loss, Exercise |
Serum Plasma DNA |
|
Gait Speed
SPPB CPET |
Actigraph (Wrist) |
MMSE |
RAINS
(Kritchevsky, WFU) |
M/F | 65 -85 | Overweight/obese; at risk for disability | 67 | 4-month intervention Nutrition (protein) supplementation |
Serum Plasma |
|
|||
REACT II
(Berry, WFU) |
M/F | 37 -95 | COPD | 200 | 12-month RCT Aerobic Exercise |
Serum Plasma Muscle DNA |
DEXA
|
Grip Strength SPPB PAT-D Knee Extensor* |
CES-D |
|
REACT III
(Berry, WFU) |
M/F | 45 -80 | COPD | 32 | 4-month RCT Resistance Exercise vs. Control |
Serum Plasma Muscle DNA |
|
|||
SECRET
(Kitzman, WFU) |
M/F | 60 + | Overweight/obese; heart failure | 100 | 5-month RCT Caloric Restriction vs. Aerobic Exercise vs. CR+AEX |
Serum Plasma Muscle DNA |
DEXA
|
Gait Speed
Grip Strength SPPB PAT-D Leg Press |
ActivPAL* |
|
SECRET-II
(Kitzman, WFU) |
M/F | 60 + | HFpEF | 88 | CR+AT vs CR+AT+FT 24 weeks |
MRI
DEXA* |
Gait Speed
SPPB* |
CES-D* |
||
SILVER
(Beavers, WFU) |
M/F | 60 -79 | Obesity | 24 | hypocaloric dietary intervention soy based meal replacemts vs animal protein based MR 3 months |
Serum Muscle DNA |
CT
DEXA |
Gait Speed
Grip Strength SPPB ESPPB* Knee Extensor |
MMSE |
|
Skeletal MRI
(Kitzman, WFU) |
M/F | 60 + | Exercise Intolerance, Heart failure, preserved ejection fraction | 20 | This study will enroll 20 participants. 10 participants will be 60 years and older, have been diagnosed with HFpEF, and suffer exercise intolerance. The remaining 10 participants will be in the age and sex matched control group. 4 weeks |
Serum Plasma |
MRI
|
Gait Speed
Grip Strength* SPPB* Knee Extensor* |
CES-D* |
|
START
(Messier, WFU) |
M/F | 50 + | Arthritis | 372 | randomized trial 18 mos |
|
MoCA* |
|||
TRAIN
(Kritchevsky, WFU) |
M/F | 55 + | Heart Failure | 294 |
Serum Plasma Urine |
DEXA
|
Grip Strength SPPB PAT-D |
CES-D |
||
UNITS
(Parker-Autry, WFU) |
F | 70 + | Urinary Incontinence | 71 | Interventional (Clinical Trial) Parallel Assignment |
Urine |
DEXA*
|
ESPPB* Knee Extensor* Postural Sway* |
MoCA* |
|
UPLIFT
(Houston, WFU) |
M/F | 65 -85 | Obesity | 187 | Interventional (Clinical Trial) 18 mos |
CT
DEXA* |
Gait Speed
Grip Strength* SPPB* ESPPB* Knee Extensor* |
DSST* MoCA* CES-D* |
||
Vitamin D Supplement
(Houston, WFU) |
M/F | 70 -89 | Vitamin D insufficient | 26 | 4-month RCT Vitamin D + Calcium supplementation vs. calcium only |
Serum Plasma Muscle |
|
Gait Speed
Grip Strength SPPB ESPPB* PAT-D Leg Press Knee Extensor* Postural Sway* |
DSST* MoCA* MMSE Story Recall* CES-D* |
|
WALCS
(McDermott, NW) |
M/F | 50 + | Peripheral artery disease | 720 | observational longitudinal cohort study N/A |
Serum Plasma |
|
Gait Speed
SPPB |
3MSE |
|
WALCS II
(McDermott, NW) |
M/F | 59 + | Peripheral artery disease | 800 | observational longitudinal cohort study N/A |
Serum Plasma |
CT
|
Gait Speed
SPPB Leg Press |
Fitbit |
MMSE CES-D |
Study (PI) | Gender | Age | Disease/ Condition |
N= | Design / Intervention |
Biospecimen | Imaging | Physical | Activity Monitoring |
Cognitive / Depression |